Rob Friel: Tycho, the ramp in US will continue to be very significantly, but of course it's all a relatively small base. So what we're seeing in the US is growth in the sort of 40% to 50% range for the year. But I think as we've said in the past, it will take a little while before it sort of ramps up to the level of significance, but they're making good traction. With regard to the Siemens discussion, I think at any point in time the people at EUROIMMUN in particularly Winfried Stöcker, who is the founder is continuing to look at ways to invest in the future and to support a significant growth. In any given year, EUROIMMUN hires anywhere from 175 to 200 engineers to support the growth that they've had historically, which is as you know has been in the sort of the high teens. What happened in the Siemens situation is apparently they are looking to the exit facility in the southern part of [Germany and Winfried] had some discussions with them where we might assume some of those engineers or in fact some of the facilities. But it's only a discussion phase right now. The way I would think about it is, you just sort of thinking out a couple of years and saying to the extent that we need to continue to get engineering capability in space this maybe a way to do that, and by the way we’re also wondering if the German government might sort of participate in those transition costs. But nothing definitively, this is just as a discussion phase right now.
Rob Friel: Yes, I mean, I think it’s a little bit of timing particularly in where we saw a little bit of weakness was in the chemical sector. I mean, but I would say industrial for us, which is down slightly in the quarter and I would attribute the more sort of the timing of instrument orders. It seems like the market overall is pretty good. We actually saw - saw a growth in the US and the weakness was really more in Europe and Asia.
Rob Friel: Yes, I think China continues to be a great market for us. When you look at the growth as I think Andy mentioned it was mid teens. It can be pretty broad based all of this, if you break it into diagnostics, life sciences, and applied markets, they are all double-digit or better. So, I think, we continue to be excited about the opportunities there. I think the only year we were a little sort of cautious and I think we still continue to sort of look out for the back half and again just be - so I would say cautious about it. But I suspect rather than high single, China will probably be at least double-digits and maybe we'll get it up in the mid teens. The other thing I would say is EUROIMMUN continues to do very well there as well. I think in the first quarter they were more in the high teens. So we continue to see good demand and like I said pretty broad based.
Rob Friel: Now I don't think there will be a change. I think we still have a preference to add to the franchises with some bolt-ons, as I think I’ve said in the past, unlikely that you would see us go into - what I would call a large deal right now. So I think our preference is to continue to delever a little bit, but it will be bolt-on acquisitions and then I think as we said in the past at a minimum we'll try and keep the share count flat. So to the extent that we see a little flowed up because of either stock price increases our option exercise, we probably take that out. But I would say no intention right now to significantly reduce the shares outstanding.
Rob Friel: No. I think you have described it exactly as we anticipate it rolling out. First quarter being EUROIMMUN’s seasonally lowest quarter and had obviously a dampening effect as well as the FX. I think we'll see as we get into the second quarter - at the higher end of the range it would ramp through the year as we made progress with EUROIMMUN. And as you can do the math it will be over 100 basis points in the quarter. Fourth quarter being a little bit of an anomaly where it's an easier comp. So I think all the things you highlighted are kind of how we're thinking about it as well.
Rob Friel: That's right. We’re looking at sort of second quarter six and then it sort of continues to sort of ramp up from there.
Rob Friel: So first of all industrial was down about 1%. So just to sort of calibrate things a little bit, it was up around mid single digits in the Americas. It was sort of flattish in Europe and was down a little bit in APAC. So it's a geographic split. And I think I mentioned before, it was probably most pronounced in the chemicals or petrochemical side of the business. And again I think that was probably just timing of instrument orders. I would say for the year, we think industrial is probably low to mid single digit growth.
Rob Friel: Yes. So first of all you're correct it was life sciences. It was particularly in the pharma and biotech area. Well, having said that, there academic and government was up sort of 6% which is nice to see. But really the over performance came in pharmaceutical and specifically in the service and informatics side of the business. And so I talked a little bit about that is some of that was new product, it was Kendro, it was the new signals offering. But we are starting to get some nice traction, as we think we're somewhat uniquely situated with regard to being able to sort of meet this need that some of the pharmaceutical companies are seeing - the buzz word is digitalization of the lab. But it's really trying to make sure that they are getting the right information out of their instruments. And so it’s a combination of having ability to provide the sort of OneSource capability, but at the same time some of the analytics and electronic notebook capability that we’ve had historically. And so that really what drove some of the upside performance in the first quarter.
Rob Friel: No. I don't have the visibility into the customer. What I can tell you though is the growth was broad-based geographically. So whether you're looking China, EMEA or North America, it was also double-digits. So I would also say that the growth was pretty broad-based across the sort of diseases. So if you look at EUROIMMUN, if you look at allergy, if you look at infectious disease they also saw nice growth. So it was pretty - like I said broad-based, but I couldn't tell you what the split was between new or existing customers.
Rob Friel: So I think you're - we were pleased to see the success of the study. But I think from a pricing standpoint and I know everybody's nice to see that and we'll have that out soon is we've said for a long period of time that the purpose of this product is really to replace screening, as compared to a diagnostic test. So we want to make sure, and again the goal here is to really go out into the biochemical labs, so the labs that are doing biochemical screening today with both a simple workflow, as well as a cost structure that is close to that. So again, stay tuned. But that's our thought process around that. And again, the whole theory is to make sure that the sensitivity of Vanadis is at least similar to the current NGS assays. I think we have some arguments as to why we think it's actually better in a number of serious. But we want to make sure at a minimum that it's similar, but in the argument, easier from a workflow perspective and much more economical. With regard to the market, I mean, I think we feel - I mean, just as a rough guide, we said, if we can take 15% to 20% of the market we think that's close to $1 billion.
Rob Friel: I think that's part of it. But I would say when you look at the ramp up it's been not only in the newborn and the bio group business, but we are attracting pharmaceutical companies, we are attracting collaborations. And I think the reason for that is what we have mentioned before is that we provide not only the genetic analysis, but we show the protein or biochemical analysis. And what we're finding that's distinctive in the marketplace and I think that's becoming very attractive to a number of the collaborators and customers.
Rob Friel: Yes. I think that's a piece of it. I mean, part of it is getting the regulatory approvals. I think as we talked in the past that was not an area that EUROIMMUN had invested significantly And so, I mean, combined now we have a much more formidable regulatory capability. I think we've already filed, since the closing, some 18 submissions to the FDA. And I mentioned we're excited about getting two of them out already. So that's a big piece of it. I think the other piece of it is just expanding your commercial presence in the US market and I think the sales force within EUROIMMUN was probably in 10 people or something. And so that's just getting - sort of opening - helping them open some doors, getting a little bit more sort of brand recognition out there. And then I mentioned the other piece was, we've now transitioned all of their - the service of all of their instruments to PerkinElmer. So I think that's helpful from the standpoint of not only cost, but responsiveness to the customer. So I think there is a number of components, just increasing awareness, so in some of the trade shows the combined presence of PKI and EUROIMMUN, I think, is helpful as well. So branding, presence, regulatory, I think, those are the main drivers.
Rob Friel: So it's really both. And I think one of reasons we were sort of comfortable starting this is because we have a bundling opportunity. We’ve talked about in the past that, we do the screening for newborn and very often the confirmatory test is done through sequencing. So by us now doing the sequencing we can do both the screening and the confirmatory. I think that was sort of a natural bundling opportunity that was sort of captive business we could go after. Similarly with ViaCord, we've had a number of customers - customers approached us to see whether or not that was something we could do. So we started the business with the understanding that we had sort of some captive business we could go after. But at the same time, we thought that there was an opportunity to go out and get incremental business. And that was some of the things we talked about before is working with pharmaceutical companies and working with the Helixes of the world, et cetera. And we're starting to see that ramp nicely. So I think if you look at our $8 million to $10 million of revenue this year, it could be fairly evenly split between both of those opportunities.
Rob Friel: So, in the informatics area, I think it was penetrating new customers and a little bit of I mentioned as new products come out with ChemDraw in particular and we saw a nice renewal from existing customers. So it's in the informatics a little bit of both. I would say on the service side, it's probably mostly with existing customers where we continue to expand what we're doing with those customers. But having said that, we do get periodically some nice wins and one in particular we're ramping up in 2018.
Rob Friel: I would say the timing in the backlog was probably more in reference to some of the markets that were a little slower in the quarter, mostly notably the industrial. I would also say food as we talked about is mid single. I think we sort of look at the year, I think, that will be a bit better than that. And then I would say the third area was I mentioned in our core diagnostics business that our applied genomics business was actually down a little bit. I think for the year that's probably going to be high single-digit, double-digit grower. So that's where we saw some pretty good bookings in the first quarter and we think that will build through the year.
Rob Friel: Yes, absolutely. EUROIMMUN has already been working on that. So they are in the process of finalizing fairly large facilities in Tianjian. And similar to our approach which is to continue to ramp up manufacturing in China and sort of make products in China for China. And so that will probably come online later this year but because with the regulatory approval probably we won't see a lot of revenue from that factory probably until ’19. But that's exactly what we're trying to do is to sort of shift some of those euro costs, euro based costs to Chinese yaun base.
Rob Friel: I think there is initially a little bolus because quite frankly there was a little pent-up demand if you will. And we've been working hard to trying to get those out as quickly as possible. And I think I mentioned we - I think we filed some 18 or so in the last three months. So I don't know that we'll see that type of pace going forward. Having said that, it's a little difficult as you can appreciate sort of determining how they hit the market because we're dependent on the FDA regulatory approval, which seems to be getting better, but we'll just have to wait and see. But clearly there was a much larger amount in the first quarter. But we hope it to be sort of a steady pace, but probably not at the level you saw in the last 90 days.
Rob Friel: I don't think there is going to be anything of significance. We've talked a little bit about pruning some things within DAS and I think we'll continue to look at those. But I don't know that they will be that material. If I had to give you number it could be $50 million it could be $75 million, it could be something like, but it’s not - I don't know that it’s going to be significant.
Rob Friel: I think there is two that are sort of in the works right now that we would hope to see in the next - again this is a little difficult to predict, but probably in the next 60 days or so. And then there is I think - there's a number that we expect to come out sort of latter in the year.
Rob Friel: So, first of all we’ll say the newborn business continue to do pretty well, but it's not because of birth rates. It's because, we continue to make either expansion of menus or expansion of penetration. If you look in the US, I think birth rates are probably trending down a point to 1.5 points. And if you look in China for ‘17 they were down, we would say sort of three, in fact, you may have seen the article in the journal today and there was a recent article in The Economist that talked about the challenge that China has right now with their growth targets as their birth rates have sort of been suppressed here a little bit. So that's something that, obviously, is a bigger issue than just newborn screening. So it's not been driven - sort of the growth in the newborn business right now is not being driven by birth rate globally, but like I said on the other aspect of it.
Rob Friel: I would go back and reinforce here is that we've talked about this sort of strategic priorities for growth. So when we look across at the diagnostic businesses continuing to build out our capabilities in emerging markets, it's obviously something that's interesting to us. I think our applied genomics area is an area where we think there is a significant opportunity to spend our capabilities. I would sort of spite those two out in the DAS area clearly in the pharma services area where I think we built a nice portfolio. Food, we believe is very attractive and combined with the fact that it's fairly fragmented industry, I think provides a lot of opportunity for us. And I would say in the analytical instrument area anything that can sort of build out our consumable, revenue would be something we would be very interested.
Rob Friel: So first of all I appreciate and thanks for all your questions. And so in closing let me just reinforce that we're all excited about the opportunities moving ahead and confident in the terrific team of employees around the world who are committed to not only driving our mission, but creating even greater value for our shareholders. So thank you for your interest in PerkinElmer and have a great evening.
Andy Wilson: Hey, Sara before the next call, I just want to clarify something I said and you can attribute it to all there, it’s being my last call. But the guidance for Q2 topline of 695 and I believe I said 680. But I want to make sure and I confirm that our topline guidance for the second quarter is $695 million. Thanks.
Andy Wilson: And the way we think about that is reproductive health was sort of mid single and to Ross's point it was a little bit difficult comp in the area. Our infectious disease business which is basically China and India was up mid-teens and we saw sort of just a little slight degradation in what we call applied genomics and it was really driven by the micro fluidics business which had some difficult comps in the prior year. That can have the tendency to be a little bit cyclical because there is are instruments involved. But reproductive was mid single ad infectious disease was mid-teens.
Andy Wilson: So the next milestone for Vanadis is clearly getting CE Marked. And I think as we've said we're expecting that -- I do know before the end of this quarter, but hopefully by early third quarter. And so the idea would be that - and be able to sell that out in the back half of the year. We don’t have huge sort of expectations for that business in the second half, but call it sort of $5 million $10 million in that type of range. Your second question was referred to the genetic testing business, are you talking about with regard to 2018 or longer term…
Andy Wilson: Yes. We talked in my prepared remarks, it was around 30 basis points 20 to 30 basis points headwind on the corporation. That will flip as we make progress through the year. It will ramp through the year, the fourth quarter for EUROIMMUN will be the largest impact. So it will go from, let's say negative 30 to I would say something in the 50 to 75 basis points as we exit the year.
Andy Wilson: I think, right now we're looking at net interest income at about $60 million - just north of $60 million.
Andy Wilson: Well, there is two things going on. One is we did pay down the revolver, but it is that the net impact on net interest expense is offset by FX. So there really wasn't much savings. As far as capital was concerned, a little bit of that is timing. We have a couple of fairly big initiatives that we started at beginning this year, I think that will normalize. And some of EUROIMMUN's capital hit in the first quarter, so I think we still feel like that we're going to be within our guidelines on capital for the year, and as a result we still think we can get to 365. So it's really mainly timing.
